International Journal of Head and Neck Surgery

Register      Login

VOLUME 2 , ISSUE 1 ( January-April, 2011 ) > List of Articles

REVIEW ARTICLE

Epidermal Growth Factor Receptor and the Squamous Cell Carcinoma of the Head and Neck

Sudhir V Nair

Citation Information : Nair SV. Epidermal Growth Factor Receptor and the Squamous Cell Carcinoma of the Head and Neck. Int J Head Neck Surg 2011; 2 (1):33-36.

DOI: 10.5005/jp-journals-10001-1044

Published Online: 01-04-2011

Copyright Statement:  Copyright © 2011; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Epidermal growth factor receptor (EGFR) is over expressed in 80 to 90% of squamous cell carcinomas of the head and neck (HNSCC) and plays a role in its pathogenesis and clinical course. Several EGFR-targeted therapies have therefore been developed and tried in clinical trials in the past decade resulting in the approval of cetuximab, an EGFR monoclonal antibody as a treatment agent for HNSCC by US FDA. Even though, EGFR monotherapy so far does not have a significant effect, cetuximab in combination with radiotherapy has enhanced the overall effect of radiotherapy in these patients without enhancing significantly the overall toxicity. Hence, understanding the mechanisms of resistance and exploring new combination treatments with EGFR targeting agents are important.


PDF Share
  1. Cancer statistics 2008. CA Cancer J Clin Apr 2008;58(2): 71-96.
  2. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res Aug 1993;53(15):3579-84.
  3. An open-and-shut case. Recent insights into the activation of EGF/ErbB receptors. Mol Cell Sep 2003;12(3): 541-52.
  4. Genetic analysis of epidermal growth factor action: Assignment of human epidermal growth factor receptor gene to chromosome 7. Proc Natl Acad Sci USA Jul 1980;77(7):4188-92.
  5. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochemical and Biophysical Research Communications Jun 2004;319(1):1-11.
  6. Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface. Mol Cell Biol Sep 2005;25(17): 7734-42.
  7. A structure- based model for ligand binding and dimerization of EGF receptors. Proc Natl Acad Sci USA Jan 2004;101(4):929-34.
  8. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res Dec 2002;62(24):7350-56.
  9. Targeting the epidermal growth factor receptor in radiotherapy: Radiobiological mechanisms, preclinical and clinical results. Radiotherapy and Oncology Sep 2004;72(3):257-66.
  10. Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma. Oncologist Sep 2009;14(9):900-08.
  11. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol Sep 2006;24(25): 4170-76.
  12. Rational bases for the development of EGFR inhibitors for cancer treatment. Int J Biochem Cell Biol 2007;39(7-8):1416-31.
  13. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J Biol Chem Jun 1984;259(12):7755-60.
  14. Growth stimulation of A431 cells by epidermal growth factor: Identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci USA Mar 1983;80(5):1337-41.
  15. EGFR, HER2 and VEGF pathways: Validated targets for cancer treatment. Drugs 2007;67(14): 2045-75.
  16. Enhanced apoptosis with combination C225/ radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J Clin Oncol Nov 2000;18(21):47S-53S.
  17. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Engl J Med Feb 2006; 354(6):567-78.
  18. Cetuximab in metastatic or recurrent head and neck cancer: The EXTREME trial. Expert Rev Anticancer Ther Oct 2009;9(10):1421-28.
  19. Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer. Curr Oncol Jun 2010;17(3): 37-48.
  20. Head Neck Aug 2008; 30(8):1040-44.
  21. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clinical Cancer Research 2006;12(17): 5064-73.
  22. Mutations in the epidermal growth factor receptor and in K-ras are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol Sep 2005;23(25):5900-09.
  23. Molecular changes in oral cancer may reflect aetiology and ethnic origin. Eur J Cancer B Oral Oncol May 1996;32B(3):150-53.
  24. New strategies in head and neck cancer: Understanding resistance to epidermal growth factor receptor inhibitors. Clinical Cancer Research May 2010;16(9): 2489-95.
  25. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. Clin Cancer Res Dec 2008;14(23):7884-95.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.